Telerehabilitation Early After CNS Injury
Launched by TRCARE, INC. · Oct 3, 2023
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new way to help people recover from serious injuries to the brain or spinal cord, such as strokes, traumatic brain injuries (TBI), and spinal cord injuries (SCI). The focus is on using a system called HandyMotion, which allows patients to participate in rehabilitation exercises and games right from their hospital room, using a TV screen. This extra therapy aims to improve arm function during their stay in the hospital. The trial is currently looking for adult participants who have had a central nervous system injury within the last 90 days and have some movement in at least one arm to join the study.
Participants in this trial can expect to engage in fun, interactive training that they can do whenever they want during their hospital stay. To be eligible, you need to be at least 18 years old, have had a qualifying injury, and be able to follow simple instructions. It's important to note that individuals with certain serious health conditions or severe cognitive issues may not qualify for this study. Overall, this trial aims to make rehabilitation more accessible and effective for those recovering from significant injuries.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age 18 years or older
- • 2. CNS injury with onset in the prior 90 days
- • 1. For stroke: Stroke that is radiologically verified and due to ischemia or to intracerebral hemorrhage.
- • 2. For traumatic brain injury: History that is consistent with TBI; and score on the Revised Rancho Levels of Cognitive Functioning Scale is at least 6 out of 10.
- • 3. For spinal cord injury: Traumatic or nontraumatic, incomplete cervical SCI.
- • 3. At least one arm must have motor deficits that are neither very mild nor devastating (dense arm plegia). Operationally, this requires that the Visit 1 Box \& Block Test score is at least 1 block, but no more than 30 blocks, in 60 seconds.
- • 4. Possess enough arm movement to participate in therapy, including able to hold the HandyMotion device in the paretic hand(s), using an assistive device if needed.
- • 5. Informed consent signed by the subject (no surrogate consent permitted for this study)
- • 6. Able to follow simple instructions
- • 7. Study participation is not likely to be significantly limited by agitated behavior
- Exclusion Criteria:
- • 1. A major, active, coexistent neurological or psychiatric disease that would limit study participation, e.g., advanced dementia or active psychosis
- • 2. Expectation that patient's cognitive status will likely interfere substantially with playing assigned games or exercises
- • 3. Deficits in communication that interfere with reasonable study participation
- • 4. Lacking visual acuity, with or without corrective lens, of 20/50 or better in at least one eye
- • 5. Subject does not speak sufficient English to comply with study procedures
- • 6. Shoulder pain that in the judgement of the study team is likely to substantially limit the amount of TR therapy completed
About Trcare, Inc.
trcare, inc. is a pioneering clinical trial sponsor dedicated to advancing medical research and enhancing patient outcomes through innovative therapeutic solutions. With a focus on oncology and rare diseases, trcare, inc. collaborates with leading researchers and institutions to design and implement robust clinical trials that prioritize patient safety and scientific integrity. Committed to leveraging cutting-edge technology and data analytics, the company aims to streamline trial processes and accelerate the development of effective treatments, ultimately improving the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jacksonville, Florida, United States
Pomona, California, United States
Los Angeles, California, United States
Salt Lake City, Utah, United States
Philadelphia, Pennsylvania, United States
Patients applied
Trial Officials
Michael Su, MD
Principal Investigator
California Rehabilitation Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported